Search

Leukocytoclastic vasculitis (LCV) is a small vessel vasculitis characterized by immune complex depositions involving dermal post-capillary venules. Cutaneous small vessel vasculitis is most often idiopathic but may be aggravated by secondary causes, such as inflammatory conditions, infections, neoplasms, and drugs exposure.Herein, we describe two patients with a long history of rheumatoid arthritis (RA) treated with methotrexate (MTX) for more than ten years, who later developed generalized LCV with pancytopenia after a viral infection, one with herpes simplex virus, and the other with SARS-CoV-2 virus. Because of the worldwide use of MTX in treatment of RA, strict follow-up and preventive measures are needed nowadays, especially during COVID-19 pandemic, in order to avoid any infection which may provoke LCV with or without systemic manifestations. So, using MTX for treating RA or other similar disorders may be considered a double-edged sword, especially during COVID-19 pandemic.

Introduction: Several vaccine‐related cutaneous adverse events occurred following the widespread use of vaccines to prevent coronavirus disease 2019 (COVID‐19). This case series reports 25 patients with de novo or accentuated dermatologic conditions after receiving the Sinopharm, Sputnik V, AstraZeneca, or BIV1‐CovIran vaccine in Iran. Methods and Results: Twenty‐five eligible patients with a mean age of 46.80 years were investigated. The cutaneous adverse events included pityriasis rosea, zoster, viral exanthema, urticaria, bullous pemphigoid, pemphigus vulgaris, and acute generalized exanthematous pustulosis. The manifestations appeared 14.45 ± 6.98 and 20.79 ± 22.18 days following injection of the first and second doses of COVID‐19 vaccines, respectively. All patients experienced new cases of cutaneous disease other than two who developed flare‐ups of lichen planus and psoriasis. Conclusion: Several cutaneous reactions, ranging from allergic events to skin diseases, have been reported following the injection of COVID‐19 vaccines. Focal injection‐site reactions are the most common cutaneous adverse events; however, de‐novo skin diseases and a flare‐up of preexisting cutaneous disorders have also been described. Although many cases of COVID‐19 vaccine‐related cutaneous diseases have been published, our zoster/lichen planus and AGEP cases after vaccination are interesting. A more detailed understanding of cutaneous adverse events following COVID‐19 vaccination will facilitate better diagnosis and management. [ABSTRACT FROM AUTHOR]

Background: Psoriasis as a common cutaneous inflammatory disease affect many aspects of patients' life. Disease registries render it possible to collect valuable data regarding a disease prevalence and burden as well as long‐term observations concerning possible therapeutic regimens. Methods: This registry was designed for the ongoing systematic data collection on patients with psoriasis at two referral dermatology centers in Iran. The pilot phase of the registry was used to identify possible obstacles in the application and execution of systematic registration. Results: A total of 281 patients were registered with the mean age of 42.02 years. The disease duration was 12.06 ± 10.90 years with the variety of clinical presentations. There was no significant difference between males and females in the age of disease onset (p = 0.53). Notably, 167 patients had children. Among them, 13 had children with psoriasis. The gender of the affected parent did not affect the possibility of psoriasis transmission to the child, and no significant difference was seen between the two sexes (P = 0.569). Regarding treatment, 99.4% of patients (n = 280) had used topical agents, 52.3% (n = 147) biologics, and 60.9% (n = 171) nonbiologic medications. Conclusion: Clinical trials report the efficacy and safety data regarding limited study populations in a restricted time window, and the results may differ from the general population. This highlights the importance of registry‐based studies for collecting and analyzing longitudinal information. In terms of long‐term disease complications such as malignancies, cardiovascular events, and serious adverse events, registry‐based studies will help clinicians better recognize and manage each disease. [ABSTRACT FROM AUTHOR]

This article discusses a pilot study that compared the effects of topical cetirizine 1% and topical diclofenac 3% with minoxidil as a conventional therapy for androgenic alopecia (AGA), or male/female pattern hair loss. AGA is a common condition that affects people of all races and ages, causing gradual hair thinning and loss. The study involved 33 male participants with AGA who were divided into three groups and received different treatments. The results showed that minoxidil had a significant improvement in hair growth, while cetirizine and diclofenac did not show significant improvements. However, cetirizine may be an option for those who do not respond to minoxidil, as it has fewer potential adverse effects. Further research is needed to fully understand the effects of topical cetirizine on AGA. [Extracted from the article]

Byline: Fahimeh. Abdollahimajd, Hamideh. Moravvej, Sahar. Dadkhahfar, Hamid. Mahdavi, Mehdi. Mohebali, Hamid. Mirzadeh Background: Chitosan has a biocompatible, biodegradable and nontoxic nature. The effectiveness of nano-chitosan films in the treatment [...]

Key Clinical Message: As dermatologists, we must be aware that even limited localized lesions may signal a life‐threatening condition, for which early diagnosis and treatment can improve the prognosis. Bullous pemphigoid is an autoimmune disorder characterized by blister formation. Hypereosinophilic syndrome is a myeloproliferative disorder featuring papules, nodules, urticarial lesions, and blisters. The coexistence of these disorders may highlight the involvement of common molecular and cellular factors. Here, we describe a 16‐year‐old patient with hypereosinophilic syndrome and bullous pemphigoid. [ABSTRACT FROM AUTHOR]

Hereditary progressive mucinous histiocytosis (HPMH) is an extremely rare progressive non-Langerhans cell histiocytic disorder presenting with only cutaneous manifestations. Patients typically present with multiple asymptomatic dome-shaped erythematous papules, usually involving the face and upper extremities. Twenty-six cases have been reported worldwide, with no spontaneous regression. Treatment with thalidomide stopped the progression of the disease in two cases. We report a case of progressive mucinous histiocytosis in a 31-year-old female patient with a history of tuberculosis who presented papular lesions on the face that later extended to the hands. She was treated with isoniazid for tuberculosis and isotretinoin for the skin lesions; the improvement was minimal during the next two months, with new lesions appearing on both hands. Thalidomide stopped the progression of the disease. The cause and pathogenesis of HPMH are undetermined. The pathogenesis of HPMH may be similar to that of lysosomal storage disease, considering the intra-cytoplasmic phospholipid deposition in both diseases, in addition to the likelihood of a role of macrophages in triggering the disease. In our patient, tuberculosis may have contributed. [ABSTRACT FROM AUTHOR]